Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
25.75
-0.40 (-1.53%)
Feb 21, 2025, 4:00 PM EST - Market closed
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 40.33, with a low estimate of 36 and a high estimate of 44. The average target predicts an increase of 56.62% from the current stock price of 25.75.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 2, 2025.
Analyst Ratings
The average analyst rating for Castle Biosciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 3 | 3 | 2 | 2 |
| Buy | 4 | 3 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Reiterates $41 | Buy | Reiterates | $41 | +59.22% | Jan 2, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $37 → $44 | Buy | Maintains | $37 → $44 | +70.87% | Nov 6, 2024 |
| Lake Street | Lake Street | Strong Buy Maintains $34 → $40 | Strong Buy | Maintains | $34 → $40 | +55.34% | Nov 5, 2024 |
| Keybanc | Keybanc | Buy Maintains $28 → $36 | Buy | Maintains | $28 → $36 | +39.81% | Nov 5, 2024 |
| Baird | Baird | Buy Maintains $37 → $39 | Buy | Maintains | $37 → $39 | +51.46% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
334.05M
from 219.79M
Increased by 51.99%
Revenue Next Year
279.58M
from 334.05M
Decreased by -16.31%
EPS This Year
0.40
from -2.14
EPS Next Year
-1.83
from 0.40
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 347.1M | 329.9M | 348.3M | |||
| Avg | 334.1M | 279.6M | 307.7M | |||
| Low | 314.7M | 248.1M | 274.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 57.9% | -1.3% | 24.6% | |||
| Avg | 52.0% | -16.3% | 10.1% | |||
| Low | 43.2% | -25.7% | -1.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.59 | -1.01 | -0.42 | |||
| Avg | 0.40 | -1.83 | -1.44 | |||
| Low | 0.26 | -2.88 | -2.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.